Rapidly progressive colonic dysplasia/neoplasia in a series of treated lung cancer patients: Is paclitaxel involved?

J Oncol Pharm Pract. 2013 Mar;19(1):82-5. doi: 10.1177/1078155211434854. Epub 2012 Feb 9.

Abstract

Incidence of second malignancies in patients with advanced lung cancer is not well-studied, in part because of a short survival in this patient population. Apart from a genetic predisposition, various environmental hazards may also be at play in their pathogenesis. Chronic smoking exposure decreases T-cell responsiveness and stimulates production of a variety of inhibitory cytokines. Paclitaxel has been associated with several immunosuppressive effects such as decreased numbers and activity of dendritic cells, NK-cells, and monocytes. We herein describe the first series of lung cancer patients who developed colonic polyps/colon cancer either during or immediately following chemotherapy with paclitaxel, suggesting a possible role of this agent in their pathogenesis.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Antineoplastic Agents, Phytogenic / adverse effects*
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Colonic Neoplasms / chemically induced
  • Colonic Neoplasms / immunology*
  • Colonic Neoplasms / pathology
  • Colonic Polyps / chemically induced
  • Colonic Polyps / immunology*
  • Colonic Polyps / physiopathology
  • Female
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / immunology
  • Male
  • Middle Aged
  • Neoplasms, Second Primary / chemically induced
  • Neoplasms, Second Primary / drug therapy
  • Neoplasms, Second Primary / immunology*
  • Neoplasms, Second Primary / pathology
  • Paclitaxel / adverse effects*
  • Paclitaxel / therapeutic use
  • Precancerous Conditions / chemically induced
  • Precancerous Conditions / immunology*
  • Precancerous Conditions / pathology

Substances

  • Antineoplastic Agents, Phytogenic
  • Immunosuppressive Agents
  • Paclitaxel